Cargando…

SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?

Detalles Bibliográficos
Autores principales:	Antonopoulou, Tania, Athanassakis, Irene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023356/ https://www.ncbi.nlm.nih.gov/pubmed/35484041 http://dx.doi.org/10.1016/j.vaccine.2022.04.061

Ejemplares similares

SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines
por: Salvatori, Giovanni, et al.
Publicado: (2020)

How do we best relax control measures as vaccine coverage for SARS-CoV-2 rises?
por: Foy, Brody H, et al.
Publicado: (2021)

Timely development of vaccines against SARS-CoV-2
por: Lu, Shan
Publicado: (2020)

Inactivated SARS-CoV-2 vaccine for people with HIV
por: Wolday, Dawit, et al.
Publicado: (2022)

Is there a post-SARS-CoV-2 vaccination dementia?
por: Fiorini, Ana C., et al.
Publicado: (2022)

Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis
por: Martin, Paul, et al.
Publicado: (2021)

Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
por: Pawelec, Graham, et al.
Publicado: (2021)

Multicomponent vaccines to fight SARS-CoV-2 variants of concern
por: Cassone, Antonio, et al.
Publicado: (2021)

The challenge of emerging SARS-CoV-2 mutants to vaccine development
por: Li, Rong, et al.
Publicado: (2021)

Questioning the justification for a fourth SARS-CoV-2 vaccine
por: Calderon-Margalit, Ronit, et al.
Publicado: (2022)

Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer
por: Denault, Elyssa, et al.
Publicado: (2022)

Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
por: Kakkassery, Helen, et al.
Publicado: (2022)

RT-qPCR Testing of SARS-CoV-2: A Primer
por: Bustin, Stephen A., et al.
Publicado: (2020)

SARS-CoV-2 RNA polymerase as target for antiviral therapy
por: Buonaguro, Luigi, et al.
Publicado: (2020)

Pregnant people deserve the protection offered by SARS-CoV-2 vaccines
por: Maykin, Melanie M., et al.
Publicado: (2021)

Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
por: Hajissa, Khalid, et al.
Publicado: (2021)

COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
por: Cevik, Muge, et al.
Publicado: (2021)

SARS-CoV-2 vaccination for immune-comprised patients: More is required
por: Li, Hui, et al.
Publicado: (2021)

Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein
por: Lim, Heeji, et al.
Publicado: (2022)

Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice
por: Sundaram, Appavu K., et al.
Publicado: (2021)

Skin rashes after SARS‐CoV‐2 vaccine: which relationship, if any?
por: Patruno, Cataldo, et al.
Publicado: (2021)

Vaccine against SARS-CoV-2 in previously infected health care workers
por: Parisi, Saverio Giuseppe
Publicado: (2021)

Increasing SARS-CoV-2 vaccination rates among Black people in Canada
por: Eissa, Azza, et al.
Publicado: (2021)

SARS-CoV-2 likely targets cellular PDZ proteins: a common tactic of pathogenic viruses
por: Rice, Andrew P, et al.
Publicado: (2021)

Pathogenicity of SARS‐CoV‐2 Omicron
por: Chu, Hin, et al.
Publicado: (2022)

Antigenic imprinting in SARS‐CoV‐2
por: Reincke, S. Momsen, et al.
Publicado: (2022)

SARS‐CoV‐2 immunogenicity at the crossroads
por: Karamloo, Fariba, et al.
Publicado: (2020)

SARS-CoV-2 Spike Protein-Expressing Enterococcus for Oral Vaccination: Immunogenicity and Protection
por: Suvorov, Alexander, et al.
Publicado: (2023)

SARS-CoV-2 vaccination in the context of original antigenic sin
por: Petráš, Marek, et al.
Publicado: (2021)

Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development
por: Cohen, Samuel A., et al.
Publicado: (2020)

The potential risks of delaying the second vaccine dose during the SARS-CoV-2 pandemic
por: Humphreys, I R, et al.
Publicado: (2021)

Why we may need to rethink future SARS-CoV-2 vaccination strategies
por: Klimek, Peter
Publicado: (2021)

Validation of the effectiveness of SARS-CoV-2 vaccines in older adults in “real-world” settings
por: Weng, Nan-ping, et al.
Publicado: (2021)

The role of observational studies based on secondary data in studying SARS-CoV-2 vaccines
por: Barda, Noam, et al.
Publicado: (2022)

Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines
por: Gaspar, Emanuelle B., et al.
Publicado: (2021)

Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines
por: Kelso, John M.
Publicado: (2021)

Platelet size as a mirror for the immune response after SARS‐CoV‐2 vaccination
por: Thiele, Thomas, et al.
Publicado: (2022)

The potential of developing a protective peptide‐based vaccines against SARS‐CoV‐2
por: Shalash, Ahmed O., et al.
Publicado: (2022)

Evaluation of vaccine effectiveness against SARS‐CoV‐2 variants by serological epitope profiling
por: Li, Cheng, et al.
Publicado: (2023)

COVID-19 and Diagnostic Testing for SARS-CoV-2 by RT-qPCR—Facts and Fallacies
por: Bustin, Stephen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_musn8inqaunhp36il0l94c2i8r